Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2

Yun Hee Baek, Jihye Um, Khristine Joy C. Antigua, Ji-Hyun Park, Yeonjae Kim, Sol Oh, Young-il Kim, Won-Suk Choi, Seong Gyu Kim, Ju Hwan Jeong, Bum Sik Chin, Halcyon Dawn G. Nicolas, Ji-Young Ahn, Kyeong Seob Shin, Young Ki Choi, Jun-Sun Park & Min-Suk Song

To cite this article: Yun Hee Baek, Jihye Um, Khristine Joy C. Antigua, Ji-Hyun Park, Yeonjae Kim, Sol Oh, Young-il Kim, Won-Suk Choi, Seong Gyu Kim, Ju Hwan Jeong, Bum Sik Chin, Halcyon Dawn G. Nicolas, Ji-Young Ahn, Kyeong Seob Shin, Young Ki Choi, Jun-Sun Park & Min-Suk Song (2020) Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2, Emerging Microbes & Infections, 9:1, 998-1007, DOI: 10.1080/22221751.2020.1756698

To link to this article: https://doi.org/10.1080/22221751.2020.1756698

© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd

Accepted author version posted online: 20 Apr 2020. Published online: 18 May 2020.

Article views: 3006

View Crossmark data
Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2

Yun Hee Baek D, E, Jihye Um A, B, Khristine Joy C. Antigua D, E, Ji-Hyun Park A, Yeonjae Kim F, Sol Oh A, Young-il Kim A, Won-Suk Choi A, Seong Gyu Kim A, Ju Hwan Jeong A, Bum Sik Chinn, Halcyon Dawn G. Nicolas D, E, Ji-Young Ahn D, Kyeong Seob Shinn, Young Ki Choi A, Jun-Sun Park B and Min-Suk Song A

A Department of Microbiology, Chungbuk National University College of Medicine and Medical Research Institute, Cheongju, Republic of Korea; B Research Institute of Public Health, National Medical Center, Seoul, Republic of Korea; C Center for Infectious Diseases Research, Department of Internal Medicine, National Medical Center, Seoul, Republic of Korea; D School of Biological Sciences, Chungbuk National University, Cheongju, Republic of Korea; E Department of Laboratory Medicine, Chungbuk National University College of Medicine, Cheongju, Republic of Korea

ABSTRACT

The previous outbreaks of SARS-CoV and MERS-CoV have led researchers to study the role of diagnostics in impediment of further spread and transmission. With the recent emergence of the novel SARS-CoV-2, the availability of rapid, sensitive, and reliable diagnostic methods is essential for disease control. Hence, we have developed a reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for the specific detection of SARS-CoV-2. The primer sets for RT-LAMP assay were designed to target the nucleocapsid gene of the viral RNA, and displayed a detection limit of 10^2 RNA copies close to that of qRT-PCR. Notably, the assay has exhibited a rapid detection span of 30 min combined with the colorimetric visualization. This test can detect specifically viral RNAs of the SARS-CoV-2 with no cross-reactivity to related coronaviruses, such as HCoV-229E, HCoV-NL63, HCoV-OC43, and MERS-CoV as well as human infectious influenza viruses (type B, H1N1pdm, H3N2, H5N1, H5N6, H5N8, and H7N9), and other respiratory disease-causing viruses (RSVA, RSVB, ADV, PIV, MPV, and HRV). Furthermore, the developed RT-LAMP assay has been evaluated using specimens collected from COVID-19 patients that exhibited high agreement to the qRT-PCR. Our RT-LAMP assay is simple to perform, less expensive, time-efficient, and can be used in clinical laboratories for preliminary detection of SARS-CoV-2 in suspected patients. In addition to the high sensitivity and specificity, this isothermal amplification conjugated with a single-tube colorimetric detection method may contribute to the public health responses and disease control, especially in the areas with limited laboratory capacities.

ARTICLE HISTORY

Received 26 February 2020; Revised 8 April 2020; Accepted 9 April 2020

KEYWORDS SARS-CoV-2; COVID-19; reverse transcription-loop-mediated isothermal amplification; molecular diagnosis; colorimetric detection; novel coronavirus

Introduction

Among the coronaviruses, the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have caused threats to public health in 2002 and 2012 [1–10]. By the end of December 2019, another zoonotic human coronavirus has emerged in Wuhan, Hubei Province of China [5,10–20]. Initially, 27 patients with clinical manifestations of pneumonia, fever, difficulty in breathing, and chest radiographs with bilateral lung infiltrative lesions were observed [10–13,16,20–22]. All patients were clinically tested negative for both the MERS-CoV and SARS-CoV [13]. An abrupt increase in cases of viral pneumonia of unknown etiology led the Chinese authorities to report the situation to the World Health Organization (WHO) on December 31, 2019 [11,12]. During the ongoing scientific investigations, WHO initially proposed the interim name of this novel virus as “2019-nCoV,” but later, COVID-19 was designated as the official name of this disease [23]. Following a thorough assessment of phylogeny, taxonomy, and established practice, the International Committee on Taxonomy of Viruses (ICTV) formally recognized this virus to be related to SARS-CoVs, and designated this virus as “SARS-CoV-2” [24].

SARS-CoV-2 falls into the genus betacoronavirus, with a sequence homology of 80–89% with coronaviruses discovered in humans, bats, and other wild animals (for instance, SARS-CoV and bat SARS-like CoV) [3,5,7,16–18,20,22]. Due to an increase in the risk of a potential spread of this virus to countries with weaker health systems, the WHO have declared the SARS-CoV-2 outbreak as a disease of “public health
emergency of international concern” [25]. Owing to the current disease situation, this novel coronavirus may remarkably become the third coronavirus posing significant threats to public health worldwide.

The impediment of further spread and transmission of this disease requires rapid and reliable identification, especially in areas with limited laboratory capacity. Concurrently, in hospitals, the identification of the causative agents of recurrent acute respiratory infections requires routine and confirmatory diagnosis through quantitative real-time polymerase chain reaction (qRT-PCR). In recent years, the loop-mediated isothermal amplification (LAMP) method that includes an exponential amplification of specific nucleic acid sequences at a constant temperature, has been widely utilized for the rapid detection of virus-specific genes [26,27]. The specificity and sensitivity of this method is generally comparable to those of the conventional PCR and qRT-PCR. The LAMP assays merged with reverse transcription steps have been developed for the detection of RNA viruses, including SARS-CoV, MERS-CoV, influenza, and other respiratory viruses [26–32].

In the present study, a single-tube reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay has been developed for the detection of the SARS-CoV-2 nucleocapsid (N) gene through colorimetric visualization. The study was aimed to develop a rapid, simple and sensitive molecular detection assay for the novel coronavirus that can differentiate it from other currently circulating human coronaviruses, including OC43, 229E, NL64, and MERS-CoV as well as other respiratory viruses. This method enables the detection of SARS-CoV-2 within 30 min, excluding RNA extraction, with the detection limit of 10² RNA copies which is close to qRT-PCR. Furthermore, by combining the amplification process with colorimetric detection, the assay is suitable for rapid and simple diagnosis within poorly equipped primary hospitals and laboratories, and in situations where an urgent diagnosis is needed.

Materials and methods

RT-LAMP primer designing

The RT-LAMP primers were designed for the detection of SARS-CoV-2 based upon the already available sequences in Global Initiative on Sharing All Influenza Data (GISAID) (www.gisaid.org). The sequences were aligned using CLC Genomics Workbench 10.0.1 (Qiagen, USA). A conserved region was identified in the target N gene sequence (GenBank Accession no: NC_045512, position 28,285–28,529) that was used as a template for the designing of the RT-LAMP primers.

To identify the most efficient primer set, seven sets of specific RT–LAMP primers were initially designed using the PrimerExplorer V4 (Eiken Chemical Co. LTD, Tokyo, Japan) programme based upon the published sequence of the N gene. Primer sets included two external primers (forward outer primer F3 and backward outer primer B3), two internal primers (forward inner primer FIP and backward inner primer BIP), and two loop primers (backward loop primer LB and forward loop primer LF). All primers were synthesized by Bionics, Inc. (Republic of Korea). Table 1 represents the detailed information regarding all the designed primer sets. Further, 9 contributing laboratories are gratefully acknowledged for sharing their sequences and metadata in GISAID for designing primers for this assay (Supplementary Table 1).

Viral RNA synthesis and extraction from cell-cultured viral samples

Initially, primers containing T7 RNA Polymerase promoter were designed using BetaCoV/Wuhan-Hu-1/2019 (GISAID, EPI_ISL_402125) sequence for SARS-CoV-2 and SARS-CoV/HKU-39849 (GenBank, Accession no.: AY278491.2) sequence, and outsourced from Bionics, Inc (Republic of Korea). The T7–flagged PCR product was then synthesized for in vitro transcription. The details of sequence and primers used for the RNA synthesis are provided in Supplementary Table 2. The artificial SARS-CoV-2 and SARS-CoV RNA was synthesized using MEGAscript™ Kits (Invitrogen, USA) following the manufacturer’s instructions. RNA was recovered through lithium chloride precipitation and stored at −80 °C till further use. For quantification of RNA transcript, RNA copy number using EndMemo DNA/RNA Copy number calculator (http://endmemo.com/bio/dnacopynum.php) was calculated, quantitated using Qubit RNA HS Assay Kit (Thermo Fisher Scientific Inc., Massachusetts, USA) following the manufacturer’s instructions, and the end-point diluted RNA was confirmed through qRT-PCR.

Moreover, BetaCoV/Korea/NMC01/2020 and Beta-CoV/Korea/NMC02/2020 viruses were propagated and passaged twice in Vero cells. Vero cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Gibco-Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS) and 1% antibiotics, and incubated at 37 °C in 5% CO₂. Intact viral RNA was extracted using RNeasy mini kit (Qiagen, USA) followed the manufacturer’s instructions. The viral RNA was stored at −80 °C till further use. The complete experimental work with SARS-CoV-2 was conducted in Enhanced Biosafety Level 3 (BL-3+) facility at Chungbuk National University as approved by the Korea Center for Disease Control.
Optimization of the RT-LAMP reaction condition using in vitro transcribed RNA

To optimize the sensitivity and specificity of RT-LAMP detection, different primer concentrations (2.5–20 μM for external primer F3 and B3, 20–80 μM for internal primer FIP and BIP, and 5–40 μM for loop primer LF and LB) were tested. For a 10 μL RT-LAMP reaction, a master mix solution was prepared containing of WarmStart® Colorimetric LAMP 2X Master Mix (NEB, UK) (5 μL), F3 and B3 primers (1 μL each), FIP and BIP primers (1 μL each), and LF and LB primers (1 μL each). The optimized final concentrations of all primers are represented in Table 1.

The RNA template (2 μL) (extracted from virus and/or synthesized RNA) was added to the master mix and the RT-LAMP reaction was performed at 65 °C. Detection limit determination was performed by processing tenfold serially diluted (1 × 1011 to 1 × 100) synthesized RNA was processed for parallel testing with RT-LAMP assay and qRT-PCR. The serially diluted RNA (2 μL) was ten-fold serially diluted to 10−3 copies of the reaction using 109, 108, 107, and 106 RNA copies. Positive RT-LAMP reactions resulted in a color change of phenol red pH indicator from pink to yellow due to decreased pH in the presence of an extensive DNA polymerase activity. Thus, the results could be directly observed by naked eye. The results from RT-LAMP reactions were also confirmed through 2% agarose gel electrophoresis.

Confirmation of the sensitivity and specificity of RT-LAMP for the detection of SARS-CoV-2 using intact viral RNA

The sensitivity of the developed RT-LAMP assay to detect SARS-CoV-2 was confirmed using the cell propagated cultures of SARS-CoV-2 that were grown and passaged twice in Vero cells. This intact viral RNA was ten-fold serially diluted to 10−9 and processed for parallel testing with RT-LAMP assay and qRT-PCR. The serially diluted RNA (2 μL) was mixed with the optimized master mix and subjected to RT-LAMP assay as described previously [32].

To determine the specificity of the optimized RT-LAMP assay for targeting SARS-CoV-2, the assay was tested across three-panel sets of different RNA samples that were extracted from patients’ nasal swabs and/or cell-propagated isolates of respiratory disease-causing agents. The RT-LAMP was cross-tested against a panel set of RNA samples of related coronaviruses, which includes human coronavirus 229E (229E), human coronavirus NL63 (NL63), human coronavirus OC43 (OC43), and Middle East Respiratory Syndrome coronavirus (MERS-CoV) tested using the developed RT-LAMP assay. The optimized RT-LAMP assay was also tested against a panel of human infecting and avian influenza viruses. The RNA samples of A/California/04/2009 (H1N1pdm), A/Perth/16/2009 (H3N2), B/Brisbane/60/2008 (Victoria lineage), and B/Phuket/3073/2013 (Yamagata lineage); highly pathogenic avian influenza viruses, including H5N1, H5N6, H5N8, and H7N9; and low pathogenic avian influenza viruses, including H2, H4–H12 were also tested for any reactivity [32].

Furthermore, a panel set of other respiratory disease-causing viruses, including adenovirus (AdV), parainfluenza virus (PIV), human metapneumovirus (MPV), human bocavirus (HboV), human rhinovirus (HRV),

Table 1. Primers for the detection of the novel Severe Acute Respiratory Syndrome-Coronavirus – 2 (SARS-CoV-2) through Reverse Transcription-Loop-Mediated Isothermal Amplification (RT-LAMP).

| Target gene | Primer name | Sequence (5′-3′) | Primer final conc. (μM) | Gene position |
|-------------|-------------|-----------------|------------------------|--------------|
| Nucleocapsid (N) | nCoV N-F3 | TGGACCCCAAAATCGCG | 5 | 28285–28302 |
|              | nCoV N-B3 | AGCCAATTTGCTCATCTGGA | 5 | 28510–28529 |
|              | nCoV N-FIP | CTTGTTTATGCGCGGCCCTC-ATTACGTTG TGACCCCT | 20 | 28373–28392 + 28316–28335 |
|              | nCoV N-BIP | ATATCGCTTTGTCACCCG-ATTGAAACGCTTGGTCCCT | 20 | 28416–28437 + 28476–28494 |
|              | nCoV N-LF | TGCCGTTCCTCATCCTGGTACT | 5 | 28349–28370 |
|              | nCoV N-LB | TCCTACTCAACATGGCAAGGA | 5 | 28438–28459 |
respiratory syncytial virus A (RSVA), and respiratory syncytial virus B (RSVB) were tested. Clinical samples of human respiratory viruses were obtained from the Chungbuk National University Hospital in the Republic of Korea. The MERS-CoV Korean isolate (MERS-CoV/KOR/KNIIH/002_05_2015, GenBank, Accession no.: KT029139) was kindly provided by the Korea Centers for Disease Control and Prevention (KCDC). All work with MERS-CoV was conducted in Enhanced Biosafety Level 3 (BL-3+) facility approved by the Korea Center for Diseases Control at Chungbuk National University. The SARS-CoV-2 qRT-PCR was performed following the protocol used for the optimization and the sensitivity assay. All viruses used in the panel were also confirmed for viral RNA using one-step RT–PCR using their specific primers. The detailed information about the primers and PCR conditions used for these panel viruses is presented in Supplementary Table 3.

Clinical evaluation of the RT-LAMP assay for SARS-CoV-2 detection

Fourteen nasal swabs collected from COVID-19 patients in the National Medical Center, Republic of Korea were processed for viral RNA extraction. Purified RNA was used for the clinical evaluation of the RT-LAMP assay in comparison to the qRT-PCR method as described above. An agreement between the two tests was also evaluated using Cohen’s Kappa.

Ethics statement

Clinical samples were collected from the National Medical Center, South Korea. Samples were collected under the approved guidelines and relevant regulations. The Ethics Committee and Institutional Review Board of National Medical Center (IRB no. H-2002-111-002) approved all experimental procedures. All experiments were performed following the approved guidelines.

Results

RT-LAMP primer designing and standardization

Twenty-eight sequences of SARS-CoV-2 deposited in GISAID were aligned. We designed the oligonucleotide primer sets to target the conserved region of the N-gene sequence which exhibited zero mismatches with the highly conserved region, specifically from position 28,285 to 28,529 (Figure 1(A and B)). We performed the RT-LAMP assay using in vitro transcribed 2 μL of 1 ng/mL RNA (1.2 × 10^7 number of copies) of the SARS-CoV-2 N gene. A successful RT-LAMP reaction results in a colorimetric reaction which includes a change in the colour of phenol red pH indicator from pink to yellow (Figure 1(C)). Moreover, successful amplifications were indicated by a typical ladder-like pattern when electrophoresed in 2% agarose gel (Figure 1(C)).

Optimization of the RT-LAMP using viral RNA

To optimize the RT-LAMP, and determine its limit of detection, a ten-fold serial dilution of the RNA transcript (1 × 10^5 to 1 × 10^1 per reaction) was used as the template in both the RT-LAMP (65°C, 60 min) (Figure 2(A)) and qRT-PCR (Figure 2(B)) assays. The standard curve for the qRT-PCR, and associated linear regression, was created using GraphPad Prism (Supplementary Figure 1). For this serial dilution, the RT-LAMP assay was able to detect down to 10^2 copies per reaction. Ten repetitions of the RT-LAMP assay containing 10^3, 10^2, and 10^1 RNA copies per reaction resulted in 100%, 90%, and 30% detection rate, respectively, while the qRT-PCR detected 100% in 10^3, 10^2, and 10^1 RNA copies and 0% in 10^0 RNA copies per reaction (Figure 2(A and B)). Nonetheless, compared to RT-LAMP, qRT-PCR method consistently detected up to ten-fold lower (10^1) RNA copies across ten reactions (qRT-PCR mean Ct=37.43) (Supplementary Table 4).

While discerning the optimal reaction time for the RT-LAMP assay, a clear colorimetric change was evident at 30 min. The clarity of the colorimetric change at 20 min was hard to discern by eye; however, a ladder-like pattern was exhibited through agarose gel electrophoresis (Figure 2(C)). Further assessment between 30 and 60 min incubation times showed 100% positive detection with 10^3 copies of RNA per reaction to be observed at both time points (across ten repetitions). For 10^2 copies per reaction, the positive detection rate was 90% for 30 min and 100% for 60 min (across ten repetitions). Moreover, during the ten repetitions, the RT-LAMP was observed to possess an equal detection rate of 30% for detecting 10^1 RNA copies at both the time points (Figure 2(D)).

In terms of overall time efficiency, excluding the RNA extraction, qRT-PCR takes 100 min to complete and obtain results (Figure 2(E)). The RT-LAMP assay developed in the present study has shown a capability of sensitive detection within 30 min similar to that of 60 min incubation. Hence, for the succeeding evaluation, the RT-LAMP assay was set in 30 min incubation time point.

Sensitivity evaluation of the RT-LAMP assay in detecting intact viral RNA

The sensitivity of the RT-LAMP assay was tested to detect the intact viral RNA that was extracted from the cell culture supernatants of two isolates from COVID-19 patients. The sensitivity was observed to
be ten-fold lower than that of the qRT-PCR, which was similar to that of the RT-LAMP assay performed using the synthesized RNA. Both assays were able to detect SARS-CoV-2 in a reaction in which intact viral templates were used (Figure 3(A and B)). Interestingly, SARS-CoV-2 positive samples were confirmed in both assays. Both the qRT-PCR and RT-LAMP reactions were able to detect intact viral RNA concentration in the range of $10^{-2}$ to $10^{-7}$ dilutions. Significantly, qRT-PCR exhibited ten-fold ($10^{-8}$) higher detection rate for the two intact viral RNA samples. The mean Ct values observed (across three repetitions) are indicated in Figure 3(C and D).

The detection limit of RT-LAMP was determined using ten repetitions of serially diluted templates ($10^{-6}$, $10^{-7}$ and $10^{-8}$) for 30 and 60 min incubation (Figure 3(E and F)). 100% detection was observed in all ten replicates of RNA diluted to $10^{-6}$ in both the patient isolates regardless of incubation period. However, the RNA samples of $10^{-7}$ concentrations were observed with lower detection rate of 50-60% in 30 min and 60-70% in 60 min incubation. Moreover, ten replicates of similar serially diluted templates ($10^{-7}$, $10^{-8}$ and $10^{-9}$) were subjected to qRT-PCR which demonstrated a ten-fold higher detection rate in agreement with the RT-LAMP results using the synthesized RNA as template (Supplementary Table 4).

Figure 1. SARS-CoV-2 nucleocapsid (N) gene sequences and RT-LAMP primer designing. A. The sequences were downloaded from GISAID, the alignment of available sequences was done to design the primer sets which targets the N gene. LAMP primers F3, F2, F1, B1, B2, B3 and loop primers LF and LB locations were highlighted as shown. B. LAMP primer sets designed from the target sequences from position 28,285 to 28,529 have a Forward Inner Primer (FIP) and Backward Inner Primer (BIP), both containing sequence complementary (F1c, B1c) to F2 and B2, respectively. C. RT-LAMP optimized using the final selected primer set. The description and sources for each sequence have been indicated in the acknowledgment section. The positive RT-LAMP amplification was optimized using the Primer set enlisted in Table 1. Lane M: 100 bp DNA ladder; Lane N: negative control, lane P: results from the RT-LAMP amplification.

**Specificity of the RT-LAMP for viral RNA**

We have examined the specificities of SARS-CoV-2 RT-LAMP assay against coronaviruses, such as human coronaviruses (OC43, NL63, and 229E), MERS-CoV, influenza viruses, and other respiratory disease-causing viruses. No amplification was observed in RT-LAMP assay for any of the viral RNA panel of related coronaviruses (Figure 4(A). upper panel). This was further confirmed after the gel electrophoresis (Figure 4(A), middle panel). The presence of viral RNA was confirmed for all samples through RT-PCR and gel electrophoresis as shown in the lower panel of Figure 4(A).

Since the signs and symptoms of SARS-CoV-2 are similar to those of influenza virus infection, a panel of highly pathogenic avian influenza viruses and human infectious influenza viruses was tested (Figure 4(B)). No cross-reactivity was observed in RT-LAMP, either through colorimetric detection or agarose gel electrophoresis. Similar results were obtained when the developed RT-LAMP assay was tested using a panel of avian influenza viruses (Figure 4(C)). These results suggest that the developed assay has a high specificity for SARS-CoV-2 against all viruses tested which manifest and/or cause respiratory clinical signs and symptoms.
Evaluation of the RT-LAMP assay using clinical specimens

A total of 154 clinical samples were evaluated which comprised of 14 positive nasal swab specimens collected from previously diagnosed patients with COVID-19 in National Medical Center, Republic of Korea, and 85 nasal swab specimens collected during the outbreak, and previously confirmed in the hospital for other respiratory disease-causing viruses. In addition, 55 samples confirmed for other respiratory disease-causing viruses and collected prior to the outbreak were also evaluated. In the collected specimens, 16 out of 154 samples were observed to react positively in the RT-LAMP assay (Table 2). Out of 16 samples, 14 were from respiratory samples of COVID-19 patients. Out of 140 negative samples used for this evaluation, two (1.33%) samples were observed to show a positive reaction (Table 2). Using qRT-PCR, we confirmed that both specimens exhibited a false-positive reaction in RT-LAMP (data not shown). We also tested 14 respiratory samples through qRT-PCR. Results revealed that all collected specimens showed positive amplification with Ct value ranging from 21.11 to 32.76. The results of the developed RT-LAMP assay showed a calculated sensitivity of 100% and a specificity of 98.70% which suggests that the primers used in this assay can be used for a sensitive and specific early detection method to identify SARS-CoV-2 cases.

Discussion

In the RT-LAMP method, primers that were designed to target the nucleocapsid (N) protein gene were utilized. In general, the gene encoding N protein was found to have the most abundant expression of subgenomic mRNA (sgmRNA) during infection [35–37]. The coronavirus’ N protein lacks the glycosylation site and possesses distinctly unaltered immunological characteristics [38]. Hence, this protein has been selected as the main target for nucleic acid amplification. Apart from being the most abundant throughout the infection, the gene encoding N protein is highly conserved among all coronavirus structural proteins. Based upon their reported pair-wise patristic distances (PPD) value differences, the emergence of SARS-CoV-2 (PPD: 2.6) was completely independent of SARS-CoV (PPD: 0.16) that emerged in 2002 [24]. Hence, this explains how specific MERS-CoV or SARS-CoV primers limitedly detect this virus and supports why
The primers utilized in the RT-LAMP assay are highly specific to SARS-CoV-2 N gene.

The limit of detection revealed that the developed assay is highly capable of detection and nearly as sensitive as qRT-PCR. We have demonstrated that the RT-LAMP assay is specific for SARS-CoV-2 and it possesses rare cross-reactivity with other viruses that manifest similar respiratory disease. Moreover, this assay can discriminate currently co-circulating common human coronaviruses and MERS-CoV. The data presented supports that the RT-LAMP is as specific as qRT-PCR in detecting SARS-CoV-2. In *in silico*

**Figure 3.** Sensitivity evaluation of the RT-LAMP using intact viral RNA of SARS-CoV-2. RT-LAMP was performed using RNA extracts from cell propagated viruses isolated from two patients diagnosed with COVID-19. Intact viral RNA extracts were ten-fold serially diluted ($10^{-2}$ to $10^{-9}$) and processed for detection of SARS-CoV-2. RT-LAMP positive reaction results for each virus isolate 1 (A) and isolate 2 (B) were further confirmed through qRT-PCR (C and D). Limit of detection was assessed using $10^{-6}$, $10^{-7}$ and $10^{-8}$ dilutions in ten repetitions, carried out at 65°C for 30 and 60 min incubation (E and D). Change of colour from phenol red to yellow indicates a positive reaction. RT-LAMP products were electrophoresed at 2% agarose gel for both RNAs. The ladder-like pattern indicates positive nucleic acid amplification. Cycle threshold (Ct) values were also indicated in each figure as a result of the qRT-PCR; Lane M: 100 bp DNA ladder; N.D: No detection. *: Limit of detection of qRT-PCR was evaluated using ten repeats of $10^{-7}$, $10^{-8}$ and $10^{-9}$ diluted RNA and the results are shown in Supplementary Table 4.

**Figure 4.** Determination of specificity of the RT-LAMP for SARS-CoV-2. RT-LAMP was performed against panels of A. related coronaviruses, such as human coronaviruses (OC43, NL63, and 229E), and MERS-CoV, B. human infectious influenza viruses, including highly pathogenic avian influenza viruses, and C. avian influenza viruses (low pathogenic). Each set of the panel includes Upper: RT-LAMP, Middle: RT-LAMP products electrophoresed and Lower: One-step RT-PCR Viral RNA confirmation of the samples used in the experiment. Specific primers used for confirmation of amplification of each viral RNA used from various respiratory disease-causing viruses have been indicated in Supplementary Table 2. MERS: Middle East respiratory syndrome coronavirus; B-Y: B/Phuket/3073/2013 (Yamagata lineage); B-V: B/Brisbane/60/2008 (Victoria lineage). Lane M: 1000 bp DNA ladder; PC: SARS-CoV-2 viral RNA (1ng/reaction); Lane N.C: negative control.
analysis, the cross-reactivity between SARS-CoV-2 and SARS-CoV and/or Bat SARS-like CoV would be low based upon the sequence length of the RT-LAMP primer binding regions (10.4-12.3%) (Supplementary Figure 2). In addition, the RT-LAMP assay using the synthesized RNA of SARS-CoV N gene showed positive amplification with 10^7 RNA copies per reaction (across three repetitions). This result shows 10,000-fold lower cross reactivity compared to that of SARS-CoV-2 (Supplementary Figure 2). In addition, the RT-LAMP assay using the mer binding regions (10.4-12.3%) (Supplementary analysis, the cross-reactivity between SARS-CoV-2 and SARS-CoV and/or Bat SARS-like CoV would be low based upon the sequence length of the RT-LAMP primer binding regions (10.4-12.3%) (Supplementary Figure 2). In addition, the RT-LAMP assay using the synthesized RNA of SARS-CoV N gene showed positive amplification with 10^7 RNA copies per reaction (across three repetitions). This result shows 10,000-fold lower cross reactivity compared to that of SARS-CoV-2 (Supplementary Figure 2). In addition, the RT-LAMP assay using the mer binding regions (10.4-12.3%) (Supplementary Table 2. Specificity of the SARS-CoV-2 RT-LAMP assay using RNA extracted from a clinical specimen.

| Virus* | Sample type | No. of samples | RT-LAMP | qRT-PCR†a |
|--------|-------------|----------------|---------|-----------|
| Coronavirus |            |                |         |           |
| SARS-CoV-2 | Clinical | 14             | 14      | 21.11–32.76 |
| 229E | Clinical | 9             | –       | 17.17–38.52 |
| NL63 | Clinical | 8             | 1d      | 17.18–40.91 |
| OC43 | Clinical | 10            | –       | 21.55–37.65 |
| Influenza virus | |                |         |           |
| Type B | Clinical | 30 (29)c | –       | 17.10–34.99 |
| H1N1 | Clinical | 11            | –       | 15.84–41.15 |
| H3N2 | Clinical | 30 (26) | –       | 9.16–34.89 |
| Other respiratory virus | |                |         |           |
| MPV | Clinical | 9             | –       | 19.10–39.49 |
| RSV A | Clinical | 1             | –       | 25.11     |
| RSV B | Clinical | 15            | 1d      | 16.77–28.47 |
| PIIV | Clinical | 3             | –       | 21.73–39.75 |
| AdV | Clinical | 3             | –       | 29.08–40.21 |
| HRV | Clinical | 11            | –       | 25.61–39.49 |
| Total |            | 154 (55) | 16      | 9.16–41.15 |

*Viruses in abbreviations include SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus-2; 229E: human coronavirus 229E; NL63: human coronavirus NL63; OC43: human coronavirus OC43; Type B: B/Phuket/3073/2013 H1N1pdm: A/California/04/2009; H3N2: A/Perth/16/2009; MPV: human metapneumovirus; RSVA: respiratory syncytial virus A; RSVB: respiratory syncytial virus B; PIIV: parainfluenza virus; AdV: Adenovirus; HRV: human rhinovirus.

†The cycle threshold values for all analysed viruses when processed in qRT-PCR using their respective primers indicated in the table.

aThe numbers in parentheses indicate clinical samples collected before SARS-CoV-2 outbreak.

bFalse positive reaction.

cThe cycle threshold values for all analysed viruses when processed in qRT-PCR using their respective primers indicated in the table.

EMERGING MICROBES AND INFECTIONS

Acknowledgments

We gratefully acknowledge the authors, originating and submitting laboratories of the sequences from GISAID’s EpiFlu Database used in the primer designing. All submitters of data may be contacted directly via the GISAID website, www.gisaid.org. Y.H.B., J.U., K.J.C.A, Y.K.C., and M.-S.S. designed research; Y.H.B., J.U., J.-H.P., S.O., Y.-I.K., W.-S.C, S.G.K., H.J.H., B.S.C, H.D.G.N. performed research; J.U., Y.K., J.-Y.A., K.S.S., Y.K.C., J.-S.P., and M.-S.S. analyzed data; and Y.H.B., K.J.C.A, Y.K.C., and M.-S.S. wrote the paper.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Ministry of Science and ICT (MSIT) [grant numbers NRF-2018R1A2B205086 to M.-S.S., NRF-2018R1A1A3A04077961 to Y.H.B and NRF-2018M3A9H4055769 to Y.H.B].

ORCID

Yun Hee Baek http://orcid.org/0000-0002-8453-4880
Khristine Joy C. Antigua http://orcid.org/0000-0003-0711-1873
Won-Suk Choi http://orcid.org/0000-0002-5120-0374
Ju Hwan Jeong http://orcid.org/0000-0001-7226-1507
Halyon Dawn G. Nicolas http://orcid.org/0000-0001-9409-2900
Min-Suk Song http://orcid.org/0000-0001-6073-0783
References

[1] Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181–192.

[2] de Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523–534.

[3] Du Toit A. Outbreak of a novel coronavirus. Nat Rev Microbiol. 2020;18:123.

[4] Fan Y, Zhao K, Shi ZL, et al. Bat coronaviruses in China. Viruses. 2019;11(3):210.

[5] Gralinski LE, Menachery VD. Return of the coronavirus: 2019-nCoV. Viruses. 2020;12(2):135.

[6] Hu B, Zeng LP, Yang XL, et al. Discovery of a rich gene pool of SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. PLoS Pathog. 2017;13(11):e1006698.

[7] Menachery VD, Yount BL, Debink K, et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med. 2015;21(12):1508–1513.

[8] Peiris JS, Guan Y, Yuen KY. Severe acute respiratory syndrome. Nat Med. 2004;10(Suppl. 12):S88–S87.

[9] Siddler K, Masignani V, Eickmann M, et al. SARS—beginning to understand a new virus. Nat Rev Microbiol. 2003;1(3):209–218.

[10] Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733.

[11] Wuhan-City-Health-Commission. Wuhan Municipal Health and Health Commission’s Report on Unexplained Viral Pneumonia (武汉市卫生健康委关于不明原因的病毒性肺炎情况通报). Wuhan. Committee WCH. 2020.

[12] Wuhan-Municipal-Health-Commission. Wuhan Municipal Health and Health Commission’s briefing on the current pneumonia epidemic situation in our city (武汉市卫健委关于当前我市肺炎疫情的情况通报). Committee WMH. 2019.

[13] Commission WMH. Wuhan Municipal Health and Health Committee’s Report on Unexplained Viral Pneumonia (武汉市卫生健康委员会关于不明原因的病毒性肺炎情况通报). Commission WMH. 2020.

[14] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497–506.

[15] Hui DS IA, Madani TA, Ntoumi F, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264–266.

[16] Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle. J Med Virol. 2020;92(4):401–402.

[17] Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. 2020;395:565–574.

[18] The I. Emerging understandings of 2019-nCoV. The Lancet. 2020;395(10221):311.

[19] Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern. The Lancet. 2020;395(10223):470–473.

[20] Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273.

[21] Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet. 2020;395(10223):514–523.

[22] Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–269.

[23] WHO. Novel coronavirus (2019-nCoV) situation report – 10. Geneva: World Health Organization; 2020.

[24] Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the coronavirus study group. bioRxiv. 2020. DOI:10.1101/2020.02.07.937862.

[25] WHO. Novel coronavirus (2019-nCoV) situation report – 11. Geneva: World Health Organization; 2020.

[26] Nogamine K, Hase T, Notomi T. Accelerated reaction by loop-mediated isothermal amplification using loop primers. Mol Cell Probes. 2002 Jun;16(3):223–229.

[27] Notomi T, Okayama H, Masubuchi H, et al. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res. 2000 Jun 15;28(12):E63.

[28] Bhadra S, Jiang YS, Kumar MR, et al. Real-time sequence-validated loop-mediated isothermal amplification assays for detection of Middle East respiratory syndrome coronavirus (MERS-CoV). PLoS One. 2015;10(4):e0123126.

[29] Hong TC, Mai QL, Cuong DV, et al. Development and evaluation of a novel loop-mediated isothermal amplification method for rapid detection of severe acute respiratory syndrome coronavirus. J Clin Microbiol. 2004;42(5):1956–1961.

[30] Wang H, Hong C, Zeng F, et al. Development of a real time reverse transcription loop-mediated isothermal amplification method (RT-LAMP) for detection of a novel swine acute diarrhea syndrome coronavirus (SADS-CoV) [Research Support, Non-U.S. Gov't]. J Virol Methods. 2018 Oct;260:45–48.

[31] Lee SH, Baek YH, Kim YH, et al. One-pot reverse transcriptional loop-mediated isothermal amplification (RT–LAMP) for detecting MERS-CoV. Front Microbiol. 2016;7:2166.

[32] Ahn SJ, Baek YH, Lloren KKS, et al. Rapid and simple colorimetric detection of multiple influenza viruses infecting humans using a reverse transcriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic platform. BMC Infect Dis. 2019 Aug 1;19(1):676.

[33] Naganori Nao KS, Katano H, Matsuyma S, et al. Detection of second case of 2019-nCoV infection in Japan. Tokyo: Japan National Institute of Infectious Disease, 2020.

[34] Jung YI, Park G-S, Moon JH, et al. Comparative analysis of primer–probe sets for the laboratory confirmation of SARS-CoV-2. bioRxiv. 2020. DOI:10.1101/2020.02.25.964775.

[35] Lai MM, Cavanagh J D. The molecular biology of coronaviruses. Adv Virus Res. 1997;48:1–100.

[36] Li S, Lin L, Wang H, et al. The epitope study on the SARS-CoV nucleocapsid protein. Genom Proteom Bioinform. 2003;1(3):198–206.

[37] Wu H-Y, Brian DA. Subgenomic messenger RNA amplification in coronaviruses. Proc Natl Acad Sci U S A. 2010;107(27):12257–12262.

[38] Fung TS, Liu DX. Post-translational modifications of coronavirus proteins: roles and function. Future Virol. 2018;13(6):405–430.
[39] Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med. 2005 May;37(5):360–363.

[40] Sahoo PR, Sethy K, Mohapatra S, et al. Loop mediated isothermal amplification: An innovative gene amplification technique for animal diseases. Vet World. 2016;9(5):465–469.

[41] Baek YH, Cheon HS, Park SJ, et al. Simple, rapid and sensitive portable molecular diagnosis of SFTS virus using reverse Transcriptional loop-mediated isothermal amplification (RT-LAMP). J Microbiol Biotechnol. 2018;28(11):1928–1936.

[42] Priye A, Bird SW, Light YK, et al. A smartphone-based diagnostic platform for rapid detection of Zika, chikungunya, and dengue viruses. Sci Rep. 2017;7:44778.